Pfizer Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 81.29B | 100.33B | 59.55B | 63.63B | 62.58B | -1.6% | |
| Cost of Revenue | (34.41B) | (38.24B) | (29.21B) | (21.78B) | (18.57B) | -14.8% | |
Gross Profit | 46.88B | 62.09B | 30.34B | 41.85B | 44.01B | 5.2% | |
| Operating Expenses | |||||||
| Research & Development | (13.83B) | (11.43B) | (10.58B) | (10.74B) | (11.98B) | 11.5% | |
| Selling, General & Administrative | (12.25B) | (13.12B) | (14.47B) | (14.73B) | (13.35B) | -9.4% | |
| Depreciation & Amortization | (5.19B) | (5.06B) | (6.29B) | (7.01B) | (4.91B) | -30.1% | |
Operating Income (EBIT) | 20.79B | 37.55B | 5.29B | 16.48B | 15.44B | -6.3% | |
| Non-Operating Items | |||||||
| Interest Income | 36.00M | 251.00M | 1.62B | 545.00M | 603.00M | 10.6% | |
| Interest Expense | (1.29B) | (1.24B) | (2.21B) | (3.09B) | (2.67B) | -13.6% | |
| Other Income/Expenses (Net) | 3.52B | -2.82B | -4.23B | -8.46B | -7.92B | -6.4% | |
Income Before Tax | 24.31B | 34.73B | 1.06B | 8.02B | 7.52B | -6.3% | |
| Income Tax Expense | (1.85B) | (3.33B) | (1.11B) | (28.00M) | (266.00M) | 850.0% | |
Net Income | 22.15B | 31.36B | 2.13B | 8.02B | 7.77B | -3.1% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $4 | $6 | $0 | $1 | $1 | -4.2% | |
| Weighted Avg Shares Outstanding | 5.60B | 5.61B | 5.64B | 5.66B | 5.68B | 0.3% | |
| Weighted Avg Shares Outstanding (Diluted) | 5.71B | 5.73B | 5.71B | 5.70B | 5.69B | -0.2% | |
EBITDA | 30.79B | 41.03B | 9.56B | 18.13B | 15.10B | -16.7% |
Explore PFE
PFE in the Healthcare
Large Cap